Leukemia

Leukemia is rated under 38 CFR § 4.117, the schedule for the hemic and lymphatic systems, at diagnostic code 7703. The rating logic is fundamentally different from the orthopedic codes most veterans encounter. There is no goniometer, no range-of-motion table, no question of which deficit is the most obvious. Active leukemia, or leukemia in a treatment phase, is rated at 100 percent. Full stop. The complication, and where claims go sideways, is what happens after the treatment phase ends.

That 100 percent does not run forever. The regulation builds in a mandatory VA examination at the conclusion of the treatment-phase 100 percent period, and the rating then shifts to the disease's residuals. Anemia, low platelets, immune compromise, chronic fatigue, the lingering effects of chemotherapy or a transplant, each gets rated under whatever code fits the residual. A veteran who finishes treatment and goes into remission can see the 100 percent rating drop, sometimes dramatically, if the residuals are mild. That drop is not arbitrary. It follows a defined reduction procedure, and that procedure is where a lot of the rating fight lives.

This page walks through DC 7703 and the two-phase rating structure, the mandatory post-treatment exam and the 38 CFR § 3.105(e) reduction process that has to precede any cut, how the residuals get rated once active disease resolves, and the presumptive pathways that make leukemia one of the higher-grant cancers in the dataset. Chronic lymphocytic leukemia is an Agent Orange presumptive. Several other leukemias are radiation presumptives. Documenting the exposure is often the whole case.

TL;DR

• Leukemia is rated under 38 CFR § 4.117, DC 7703, on the hemic and lymphatic schedule.
• A 100 percent evaluation applies during active disease or any treatment phase. This is automatic while the disease is active or you are in treatment.
• After the treatment phase ends, a mandatory VA examination is scheduled, and the condition is then rated on its residuals (anemia, thrombocytopenia, immune compromise, fatigue) under the appropriate codes.
• Any reduction from the 100 percent rating must follow the § 3.105(e) procedure: proposed reduction, 60-day notice, opportunity for a hearing, and a specified effective-date sequence. A cut without that process is procedurally defective.
• Chronic lymphocytic leukemia (CLL) is an Agent Orange presumptive under 38 CFR § 3.309(e), and hairy cell and other B-cell leukemias are recognized in the herbicide context.
• Leukemias other than CLL are radiation presumptives under 38 CFR § 3.309(d) for radiation-exposed veterans.
• The exposure record, Vietnam or other herbicide service, ionizing radiation, contaminated water, is usually the decisive piece of evidence.
• In Claim Raven's analysis of 558 BVA leukemia cases, 38.4 percent were granted, 31.4 percent were remanded, and 17.7 percent were denied. Of 367 cases with a C&P adequacy determination, 66.5 percent had the exam flagged as inadequate. The comparatively high grant share is consistent with the presumptive pathways.

DC 7703 and the Two-Phase Rating Structure

The hemic and lymphatic schedule treats blood cancers differently from almost everything else in the rating schedule. Most diagnostic codes assign a percentage based on the current severity of a static impairment. Leukemia is rated on its phase.

Leukemia: With active disease or during a treatment phase, 100 percent.

That is the active-phase rule. While the leukemia is active, or while you are undergoing a course of treatment for it (chemotherapy, radiation, a bone marrow or stem cell transplant, targeted therapy, the maintenance phases that follow), the rating is 100 percent. The regulation does not ask how sick you look on the day of the exam. Active disease or active treatment is the trigger, and the trigger pays the maximum schedular rating.

The second phase is the part that surprises people. The regulation continues, in substance: following the cessation of surgical, radiation, antineoplastic chemotherapy, or other therapeutic procedure, the rating of 100 percent continues with a mandatory VA examination at a defined point, and any change in evaluation based on that examination is subject to § 3.105(e). After the treatment phase, the disease is rated on its residuals.

So the structure is: 100 percent during active disease and treatment, then a mandatory exam, then a residual-based rating that could be anywhere from 100 percent down to zero depending on what the disease and its treatment left behind. This is not the limitation-of-motion logic you see in a knee or back claim, where the rating tracks a measured deficit on a sliding scale. It is a phase rating that converts to a residual rating at a defined hand-off point.

The Mandatory Post-Treatment Exam and the § 3.105(e) Reduction

The conversion from 100 percent to a residual rating does not happen quietly. Two protections sit in front of it.

First, the mandatory examination. The regulation schedules a VA examination at the conclusion of the treatment-phase 100 percent period. The point of that exam is to document what residuals remain now that active disease and treatment have ended. If the exam is not done, or is done poorly, the factual basis for any reduction is missing. An examiner who writes "leukemia in remission" without quantifying the anemia, the platelet count, the infection history, the fatigue, and the functional impact has not produced an adequate basis for a residual rating.

Second, and this is the protection veterans most often lose by not knowing it exists, any reduction from 100 percent must follow 38 CFR § 3.105(e). When a rating reduction would lower the compensation payment, VA has to issue a proposed reduction with notice, give you 60 days to submit evidence and request a predetermination hearing, and then apply the reduction only on a specified effective-date schedule. A reduction that skips the proposed-rating step, or that cuts the rating effective before the notice period runs, is procedurally defective and can be restored on that basis alone.

This matters because the most common Board issue in a leukemia case is not whether the disease is service-connected. It is whether the post-treatment reduction was done correctly. A veteran who went into remission, got an exam, and saw the rating drop from 100 percent to 30 or 10 percent has two separate arguments: that the residuals actually warrant a higher rating than VA assigned, and that the reduction itself failed the § 3.105(e) procedure. The procedural argument can win even when the medical picture is genuinely improved, because the regulation requires the process regardless of the outcome.

How the Residuals Get Rated

Once active disease and treatment have ended, the leukemia stops being rated as leukemia and starts being rated as the sum of its residuals. Each residual is rated under the code that fits it. The most common residuals after leukemia treatment, and the schedules they pull from, are:

Anemia. Chemotherapy and the disease itself can suppress red-cell production. Current 38 CFR § 4.117 uses type-specific anemia codes rather than the repealed DC 7700 hemoglobin ladder. The diagnosis and cause determine whether treatment frequency, transfusions, disease episodes, or another current criterion controls. See the anemia page for the current code split. A veteran left with a qualifying treatment-related anemia may carry a separate residual evaluation after the leukemia phase converts.

Thrombocytopenia (low platelets). Bleeding risk from a suppressed platelet count is rated on the hemic and lymphatic schedule as well, with the rating tracking the platelet count and the bleeding history.

Immune compromise. Leukemia and its treatment, especially after a stem cell or bone marrow transplant, can leave a veteran with a lasting vulnerability to infection. Recurrent infections, the need for ongoing prophylactic medication, and the functional limits that come with an impaired immune system are rated under the codes that fit the specific picture.

Fatigue and constitutional effects. Chronic fatigue, weakness, and the systemic toll of treatment are real residuals, though they are often the hardest to capture in a rating because they do not show up as a single lab value. This is where the veteran's own documentation matters most.

The residual rating is a combined rating in the ordinary sense. If a veteran finishes treatment with rateable anemia, rateable thrombocytopenia, and a separately rateable secondary condition, those combine under 38 CFR § 4.25. The pyramiding rule under 38 CFR § 4.14 still applies, so the same symptom cannot be rated twice, but distinct residuals affecting different systems are separately rateable.

The practical risk is that the post-treatment exam captures the disease status ("in remission") and skips the residual inventory. A clean remission note with no quantification of hemoglobin, platelets, infection frequency, or functional capacity produces a low residual rating by default, because the rater has nothing to rate the residuals on.

The Presumptive Pathways

Leukemia is one of the cancers where the cause-of-the-disease question is often resolved by regulation rather than by a nexus opinion. There are two main presumptive routes, and they map onto different exposures.

Agent Orange and the herbicide presumptive

38 CFR § 3.309(e) lists the diseases presumptively service-connected for veterans exposed to herbicides such as Agent Orange. Chronic lymphocytic leukemia (CLL) is on that list. For a veteran with qualifying herbicide exposure, typically boots-on-the-ground service in Vietnam, service in the Korean DMZ during the recognized period, or other locations now covered after the PACT Act expansion, a CLL diagnosis is presumed connected to service without the need to prove a medical nexus. Hairy cell leukemia and other chronic B-cell leukemias are also recognized in the herbicide context.

What you have to prove for the herbicide presumptive is the exposure and the diagnosis, not the link between them. Service in a covered location and time period establishes the exposure. The diagnosis comes from the medical record. The connection is presumed.

Ionizing radiation and the radiation presumptive

38 CFR § 3.309(d) covers diseases presumptively connected for radiation-exposed veterans, those who participated in atmospheric nuclear testing, the occupation of Hiroshima or Nagasaki, or other recognized radiation-risk activities. Leukemia, other than CLL, is on the radiation-presumptive list. So the two presumptive routes are nearly complementary on the leukemia question: CLL goes through the herbicide door, and the other leukemias go through the radiation door.

This is part of why the grant rate in the dataset runs comparatively high. When a presumptive applies, the case turns on documenting the exposure rather than on the quality of a medical opinion, and exposure can frequently be established from service records, unit histories, and the recognized location-and-date lists.

When no presumptive applies

A veteran whose leukemia is not CLL and who was not radiation-exposed, or whose exposure does not fit a recognized category, falls back to direct service connection. That route needs a current diagnosis, an in-service event or exposure, and a medical nexus linking the two. Contaminated water exposure, including the Camp Lejeune pathway, can support a claim where the documented exposure and the diagnosis line up. The nexus opinion in a direct-connection leukemia claim has to do the same work any nexus opinion does: identify the mechanism, address the time course, and rule out other causes with sound reasoning rather than a bare conclusion.

C&P Exam Mechanics: What the Examiner Has to Document

The leukemia C&P exam does different work depending on which phase the veteran is in, and that distinction is where a lot of inadequate exams come from.

During active disease or treatment, the exam mostly needs to confirm the phase. Active leukemia or an ongoing course of treatment supports the 100 percent rating, so the examiner should document the diagnosis, the current treatment regimen, and the treatment timeline. The error here is an examiner who tries to rate severity during an active phase rather than recognizing that active disease or treatment is itself the 100 percent trigger.

At the post-treatment exam, the work flips. Now the examiner has to inventory the residuals: current hemoglobin and the anemia picture, platelet count and any bleeding history, infection frequency and immune status, fatigue and functional capacity, and any organ damage or secondary conditions from the treatment. A post-treatment exam that says "remission, no active disease" and stops has not produced the residual documentation the rating depends on. That is the single most common adequacy failure in this subset.

The dataset reflects this. Of the 367 leukemia cases that had a C&P adequacy determination, 66.5 percent had the exam flagged as inadequate. That is a high rate, and it is consistent with what the two-phase structure invites: exams that confirm disease status without quantifying residuals, and reductions that follow those thin exams. When the Board remands a leukemia case, it is frequently because the post-treatment exam did not adequately characterize the residuals, or because the reduction that followed did not satisfy § 3.105(e).

Secondary Chains: What Leukemia and Its Treatment Open Up

Under 38 CFR § 3.310, a condition caused or aggravated by a service-connected disability can itself be service-connected (Allen v. Brown, on aggravation). Leukemia and the treatment for it open several downstream chains.

Treatment-induced organ damage. Chemotherapy and radiation can damage the heart, lungs, kidneys, and liver. Cardiomyopathy, pulmonary fibrosis, and treatment-related kidney impairment are recognized secondaries when the medical record connects the organ damage to the cancer treatment.

Secondary cancers. Some leukemia treatments raise the risk of a later, distinct malignancy. A second cancer that the medical evidence ties to the prior treatment can be claimed as a secondary.

Immune-related and infectious conditions. Lasting immune compromise after treatment, particularly post-transplant, can produce chronic or recurrent infections that are themselves rateable.

Mental health secondaries. A cancer diagnosis and the course of treatment frequently produce depression, anxiety, or an adjustment disorder. These are well-recognized secondaries when a clinician connects them to the underlying service-connected disease.

The standard for each chain is the same as in any secondary claim. A nexus opinion has to explain the mechanism and reasoning. "The veteran's heart condition is due to leukemia" without the pathway is not probative. An opinion that walks through the cardiotoxic chemotherapy agent, the documented cardiac decline after treatment, and the absence of a competing cause carries weight.

Common Evidence Gaps in Leukemia Claims

A few patterns I see across BVA decisions involving leukemia.

Exposure not documented for the presumptive. The single highest-value gap. A veteran with CLL who served in Vietnam, or a veteran with another leukemia who participated in radiation-risk activity, has a presumptive path, but only if the exposure is in the record. Vague service descriptions, missing unit assignments, and undocumented dates can sink a claim that the regulation would otherwise grant. Service personnel records, unit histories, and the recognized location-and-date lists are what close this gap.

Post-treatment exam that skips the residuals. When the exam at the end of the treatment phase records remission status without quantifying anemia, platelets, infection history, and fatigue, the residual rating defaults low. The rater can only rate what the exam documents.

Reductions that ignore § 3.105(e). A 100 percent rating cut to a residual rating without the proposed-reduction notice, the 60-day window, and the correct effective-date sequence is procedurally defective. Veterans who do not know the process exists often accept a reduction that could have been challenged on procedure alone.

Fatigue and functional loss left undocumented. The constitutional residuals of leukemia and its treatment, fatigue, weakness, reduced stamina, are real but hard to capture in a lab value. Without the veteran's own documentation, a symptom journal, work-absence records, statements from family or coworkers, the examiner has a thin factual basis and the rating reflects only the measurable residuals.

Treating active-phase severity instead of the phase rule. Some claims get tangled because an examiner or rater tries to assign a severity-based percentage during an active phase, when the regulation already provides 100 percent for active disease or treatment. Recognizing the phase rule avoids an under-rating during the period the law treats as total.

I do not know the exact percentage of leukemia claims that carry any one of these gaps. What I can say from Claim Raven's analysis of 558 BVA leukemia cases is that 38.4 percent were granted, 31.4 percent were remanded, and 17.7 percent were denied, and that of the 367 cases with a C&P adequacy determination, 66.5 percent had the exam flagged as inadequate. The comparatively high grant share is consistent with the presumptive pathways doing real work: when CLL plus herbicide exposure, or another leukemia plus radiation exposure, lines up, the case is often a grant. The high remand share, paired with the high inadequate-exam rate, tracks the post-treatment-exam and residual-documentation problems described above.

Bottom Line

Leukemia is not rated on a severity scale the way a joint condition is. It is rated on its phase. Active disease or an active treatment phase pays 100 percent, automatically, regardless of how the veteran presents on exam day. The hard part comes after, when the treatment phase ends, a mandatory exam is scheduled, and the rating converts to whatever the residuals support. That conversion can only happen through the § 3.105(e) reduction procedure, and a cut that skips the process is challengeable on procedure alone. On the front end, the presumptive pathways often decide the case before any nexus question is reached: chronic lymphocytic leukemia through the Agent Orange door, the other leukemias through the radiation door, with contaminated-water and direct-connection routes behind them. The veterans who do best document the exposure thoroughly, insist on a post-treatment exam that actually inventories the residuals, and hold VA to the reduction procedure when the 100 percent rating is on the table. Same diagnosis, different paper trail, different outcome.

Related Conditions

Leukemia shares rating logic and presumptive structure with the other cancers on the system, including lymphoma, which is also rated on the hemic and lymphatic schedule with a similar active-versus-residual phase rule. The Agent Orange presumptive that covers CLL also reaches prostate cancer and lung cancer, and colon cancer sits in the same exposure-driven oncology group where documenting the in-service exposure is frequently the whole case. Veterans navigating treatment residuals and the post-treatment reduction should review the secondary conditions tool before assuming the residual rating tells the whole story.

Methodology and Limitations

• Data source: Rating criteria quoted and paraphrased from 38 CFR § 4.117, DC 7703 (leukemia). Reduction procedure from § 3.105(e). Combined ratings math from § 4.25. Pyramiding from § 4.14. Secondary service connection from § 3.310. Presumptive pathways from § 3.309(e) (herbicide, including CLL) and § 3.309(d) (ionizing radiation). Case law on secondary aggravation from Allen v. Brown.
• Sample size: Patterns in this post are drawn from Claim Raven's analysis of 101,518 condition records drawn from the analyzed subset of Claim Raven's 501,000+ Board-decision library, including 558 leukemia cases. Within that leukemia subset, outcomes ran 38.4 percent granted, 31.4 percent remanded, and 17.7 percent denied. Of the 367 cases that had a C&P adequacy determination, 66.5 percent had the exam flagged as inadequate. The dataset captures overall outcome rather than a per-residual or per-presumptive-route breakdown, so I cannot read the CLL-versus-other-leukemia split or the herbicide-versus-radiation split directly from it.
• Classification approach: Diagnostic code and phase definitions drawn from the regulatory text. Presumptive analysis follows the § 3.309 lists. Reduction analysis follows § 3.105(e). Residual rating analysis follows the hemic and lymphatic schedule.
• Limitations:
• Compensation figures and tiers are governed by the current 38 CFR § 4.117 text and adjust with regulatory amendments and annual COLA.
• The presumptive lists under § 3.309 have expanded over time, including after the PACT Act. Coverage of specific locations, dates, and leukemia subtypes can change, and a claim should be checked against the current lists.
• The two-phase structure means the rating during an active phase and the residual rating after treatment are governed by different rules. Worked descriptions illustrate the structure, not a guaranteed numeric outcome.
• Selection bias: BVA-level patterns reflect cases that appealed. Most leukemia claims resolve at the RO level and are not in any BVA dataset. Presumptive grants in particular often never reach the Board.
• The high inadequate-exam rate reflects cases that were appealed and reviewed for exam adequacy, not all leukemia exams.
• These observations reflect patterns from the regulatory text, the presumptive lists, and BVA decisions. They are not predictions of individual outcomes.